


Targeted DNA/RNA Sequencing Market Size Worth US\$ 43.7 Billion by 2032 | CAGR 15.39%: IMARC Group

The global targeted DNA/RNA sequencing market size reached US\$ 12.1 Billion in 2023.

BROOKLYN, NY, UNITED STATES, February 6, 2024 /EINPresswire.com/ -- According to IMARC Group latest report titled "Targeted DNA/RNA Sequencing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032", offers a comprehensive analysis of the industry, which comprises insights on [targeted DNA/RNA sequencing market overview](#). The report also includes competitor and regional analysis, and contemporary advancements in the global market.



Targeted DNA/RNA Sequencing Market Report

The global targeted DNA/RNA sequencing market size reached US\$ 12.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 43.7 Billion by 2032, exhibiting a growth rate (CAGR) of 15.39% during 2024-2032.

Request a Free Sample Report: <https://www.imarcgroup.com/targeted-dna-rna-sequencing-market/requestsample>

Targeted DNA/RNA sequencing is a highly specialized technique in molecular biology designed for sequencing specific regions of the genome or transcriptome. This method allows researchers and clinicians to focus on specific areas of interest rather than sequencing the entire genome or transcriptome, making it a cost-effective and time-efficient approach. There are various types of targeted sequencing, including amplicon sequencing and hybrid capture sequencing, each with unique advantages. Amplicon sequencing is known for its high specificity and sensitivity, while hybrid capture offers broader coverage. The advantages of targeted sequencing include improved depth of coverage, reduced sequencing cost, and faster turnaround times. This approach is particularly advantageous in clinical settings for genetic disorder diagnosis, oncology studies, and infectious disease research, where precise and accurate genetic information is

crucial.

Market Trends:

The global targeted DNA/RNA sequencing market is experiencing significant growth, driven by the increasing prevalence of genetic disorders and cancer, as targeted sequencing plays a pivotal role in understanding these diseases at a molecular level, leading to more effective treatments. Additionally, technological advancements in sequencing technologies, offering higher accuracy and lower costs, further fuel market growth. Along with this, the expanding application of personalized medicine, which relies heavily on detailed genetic information provided by targeted sequencing, is another key trend enhancing the market. In addition, the growing investment in genomics research by both government and private entities is propelling market expansion. Apart from this, the rise in collaborations between academic institutions and biotechnology companies to develop innovative sequencing solutions is also a significant trend. Moreover, the increasing focus on precision medicine and companion diagnostics is creating a positive market outlook.

View Full Report with TOC & List of Figure: <https://www.imarcgroup.com/targeted-dna-rna-sequencing-market>

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players operating in the market.

- Agilent Technologies Inc.
- BGI Group
- Dnastar Inc.
- Eurofins Genomics LLC (Eurofins Scientific SE)
- F. Hoffmann-La Roche Ltd
- Illumina Inc.
- Integrated DNA Technologies, Inc. (Danaher Corporation)
- MacroGen Inc
- Oxford Nanopore Technologies plc
- PacBio
- PierianDx
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.

Key Market Segmentation:

Our report has categorized the market based on region, technology, workflow, application, type, and end user.

Technology Insights:

- NGS
- Others

Workflow Insights:

- Presequencing
- Sequencing
- Data Analysis

Application Insights:

- Human Biomedical Research
- Plant and Animal Sciences
- Drug Discovery
- Others

Type Insights:

- DNA-based Targeted Sequencing
- RNA-based Targeted Sequencing

End User Insights:

- Hospitals & Clinics
- Academic & Research Institutes
- Pharma & Biotech Companies

Regional Insights:

- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, South Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa

Key Highlights of the Report:

- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- Porter's Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape

About Us:

IMARC Group is a leading market research company that offers management strategy and

market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Elena Anderson

IMARC Services Private Limited

+1 631-791-1145

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/686506292>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.